Objective To evaluate the anti-hypertensive amplitude，the compliance rate of ambulatory blood pressure monitoring（ABPM），and feasible path of amlodipine -benazepril tablets（Ⅱ）［AMBE tablets （Ⅱ）］in the treatment of grade 2 essential hypertension（EH）patients uncontrolled by free combination of two antihypertensive drugs. Methods A total of 93 patients who failed to meet the standard confirmed by ABPM were treated with AMBE tablet（Ⅱ）for 4 weeks，and the antihypertensive amplitude and the compliance rate of ABPM were evaluated. Results After treatment with AMBE tablets（Ⅱ），the compliance rate of ABPM was 35.5%，with a total effective rate of 72% and ineffective rate of 28%. The results of 24 h MBP［（140.76 ± 15.62）/（89.50 ± 9.86） vs.（126.00 ± 12.05）/（79.90 ± 7.58）］，dMBP［（142.56 ± 15.98）/（90.94 ± 10.68）vs.（127.50 ± 11.95）/（81.12 ± 7.46）］，and nMBP［（134.90 ± 17.26）/（84.24 ± 9.42）vs.（121.04 ± 14.29）/（76.00 ± 10.14）］were obtained. The 24 h blood pressure load value was significantly lower than that before treatment（P < 0.01），and it was safe and had mild side effects. Conclusion AMBE tablets（Ⅱ）can safely and effectively reduce the ambulatory blood pressure range of patients（an average of 14.76/9.60 mmHg），and enhance the compliance rate of ABPM in more than 1/3 patients，indicating that it could be served effectively as a treatment path for grade 2 EH patients who failed to meet the standard of free dual antihypertensive therapy.